<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title37.html">
                                    Title 37
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/37CFR1.html">Part 1
                                </a><span>&nbsp/&nbsp<span>
                                Sec.  1.823  Requirements for nucleotide and/or amino acid
                            </h3>
                            <p class="depth1"><em>(a)</em></p><p class="depth2"><em>(1)</em> If the ``Sequence Listing'' required by Sec.  1.821(c) is  submitted on paper: The ``Sequence Listing,'' setting forth the  nucleotide and/or amino acid sequence and associated information in  accordance with paragraph (b) of this section, must begin on a new page  and must be titled ``Sequence Listing.'' The pages of the ``Sequence  Listing'' preferably should be numbered independently of the numbering  of the remainder of the application. Each page of the ``Sequence  Listing'' shall contain no more than 66 lines and each line shall  contain no more than 72 characters. The sheet or sheets presenting a  sequence listing may not include material other than part of the  sequence listing. A fixed-width font should be used exclusively  throughout the ``Sequence Listing.''</p><p class="depth2"><em>(2)</em> If the ``Sequence Listing'' required by Sec.  1.821(c) is  submitted on compact disc: The ``Sequence Listing'' must be submitted on  a compact disc in compliance with Sec.  1.52(e). The compact disc may  also contain table information if the application contains table  information that may be submitted on a compact disc (Sec.   1.52(e)(1)(iii)). The specification must contain an incorporation-by- reference of the Sequence Listing as required by Sec.  1.52(e)(5). The  presentation of the ``Sequence Listing'' and other materials on compact  disc under Sec.  1.821(c) does not substitute for the Computer Readable  Form that must be submitted on disk, compact disc, or tape in accordance  with Sec.  1.824.</p><p class="depth1"><em>(b)</em> The ``Sequence Listing'' shall, except as otherwise indicated,  include the actual nucleotide and/or amino acid sequence, the numeric  identifiers and their accompanying information as shown in the following  table. The numeric identifier shall be used only in the ``Sequence  Listing.'' The order and presentation of the items of information in the  ``Sequence Listing'' shall conform to the arrangement given below. Each  item of information shall begin on a new line and shall begin with the  numeric identifier enclosed in   angle brackets as shown. The submission of those items of information  designated with an ``M'' is mandatory. The submission of those items of  information designated with an ``O'' is optional. Numeric identifiers  <110through <170shall only be set forth at the  beginning of the ``Sequence Listing.'' The following table illustrates  the numeric identifiers.  ----------------------------------------------------------------------------------------------------------------</p><p class="depth2">Mandatory (M) or optional</p><p class="depth2">Numeric identifier            Definition              Comments and format                   (O). ---------------------------------------------------------------------------------------------------------------- <110..........  Applicant...............  Preferably max. of 10 names;   M.</p><p class="depth2">one name per line;</p><p class="depth2">preferable format: Surname,</p><p class="depth2">Other Names and/or Initials. <120..........  Title of Invention......  .............................  M. <130..........  File Reference..........  Personal file reference......  M when filed prior to</p><p class="depth2">assignment of appl. number. <140..........  Current Application       Specify as: US 07/999,999 or   M, if available.</p><p class="depth2">Number.                   PCT/US96/99999. <141..........  Current Filing Date.....  Specify as: yyyy-mm-dd.......  M, if available. <150..........  Prior Application Number  Specify as: US 07/999,999 or   M, if applicable include</p><p class="depth2">PCT/US96/99999.                priority documents under 35</p><p class="depth2">USC 119 and 120. <151..........  Prior Application Filing  Specify as: yyyy-mm-dd.......  M, if applicable.</p><p class="depth2">Date. <160..........  Number of SEQ ID NOs....  Count includes total number    M.</p><p class="depth2">of SEQ ID NOs. <170..........  Software................  Name of software used to       O.</p><p class="depth2">create the Sequence Listing. <210..........  SEQ ID NO::....  Response shall be an integer   M.</p><p class="depth2">representing the SEQ ID NO</p><p class="depth2">shown. <211..........  Length..................  Respond with an integer        M.</p><p class="depth2">expressing the number of</p><p class="depth2">bases or amino acid residues. <212..........  Type....................  Whether presented sequence     M.</p><p class="depth2">molecule is DNA, RNA, or PRT</p><p class="depth2"><em>(protein)</em>. If a nucleotide</p><p class="depth2">sequence contains both DNA</p><p class="depth2">and RNA fragments, the type</p><p class="depth2">shall be ``DNA.'' In</p><p class="depth2">addition, the combined DNA/</p><p class="depth2">RNA molecule shall be</p><p class="depth2">further described in the</p><p class="depth2"><220to <223feature section. <213..........  Organism................  Scientific name, i.e., Genus/  M</p><p class="depth2">species, Unknown or</p><p class="depth2">Artificial Sequence. In</p><p class="depth2">addition, the ``Unknown'' or</p><p class="depth2">``Artificial Sequence''</p><p class="depth2">organisms shall be further</p><p class="depth2">described in the <220to <223feature</p><p class="depth2">section. <220..........  Feature.................  Leave blank after <220. <221-223provide for a description   ``Xaa,'' or a modified or</p><p class="depth2">of points of biological        unusual L-amino acid or</p><p class="depth2">significance in the            modified base was used in a</p><p class="depth2">sequence..                     sequence; if ORGANISM is</p><p class="depth2">``Artificial Sequence'' or</p><p class="depth2">``Unknown''; if molecule is</p><p class="depth2">combined DNA/RNA'' <221..........  Name/Key................  Provide appropriate            M, under the following</p><p class="depth2">identifier for feature,        conditions: if ``n,''</p><p class="depth2">preferably from WIPO           ``Xaa,'' or a modified or</p><p class="depth2">Standard ST.25 (1998),         unusual L-amino acid or</p><p class="depth2">Appendix 2, Tables 5 and 6.    modified base was used in a</p><p class="depth2">sequence. <222..........  Location................  Specify location within        M, under the following</p><p class="depth2">sequence; where appropriate    conditions: if ``n,''</p><p class="depth2">state number of first and      ``Xaa,'' or a modified or</p><p class="depth2">last bases/amino acids in      unusual L-amino acid or</p><p class="depth2">feature.                       modified base was used in a</p><p class="depth2">sequence. <223..........  Other Information.......  Other relevant information;    M, under the following</p><p class="depth2">four lines maximum.            conditions: if ``n,''</p><p class="depth2">``Xaa,'' or a modified or</p><p class="depth2">unusual L-amino acid or</p><p class="depth2">modified base was used in a</p><p class="depth2">sequence; if ORGANISM is</p><p class="depth2">``Artificial Sequence'' or</p><p class="depth2">``Unknown''; if molecule is</p><p class="depth2">combined DNA/RNA. <300..........  Publication Information.  Leave blank after <300. <301..........  Authors.................  Preferably max of ten named    O.</p><p class="depth2">authors of publication;</p><p class="depth2">specify one name per line;</p><p class="depth2">preferable format: Surname,</p><p class="depth2">Other Names and/or Initials. <302..........  Title...................  .............................  O. <303..........  Journal.................  .............................  O. <304..........  Volume..................  .............................  O. <305..........  Issue...................  .............................  O. <306..........  Pages...................  .............................  O.</p><p class="depth2"><307..........  Date....................  Journal date on which data     O.</p><p class="depth2">published; specify as yyyy-</p><p class="depth2">mm-dd, MMM-yyyy or Season-</p><p class="depth2">yyyy. <308..........  Database Accession        Accession number assigned by   O.</p><p class="depth2">Number.                   database including database</p><p class="depth2">name. <309..........  Database Entry Date.....  Date of entry in database;     O.</p><p class="depth2">specify as yyyy-mm-dd or MMM-</p><p class="depth2">yyyy. <310..........  Patent Document Number..  Document number; for patent-   O.</p><p class="depth2">type citations only. Specify</p><p class="depth2">as, for example, US 07/</p><p class="depth2">999,999. <311..........  Patent Filing Date......  Document filing date, for      O.</p><p class="depth2">patent-type citations only;</p><p class="depth2">specify as yyyy-mm-dd. <312..........  Publication Date........  Document publication date,     O.</p><p class="depth2">for patent-type citations</p><p class="depth2">only; specify as yyyy-mm-dd. <313..........  Relevant Residues.......  FROM (position) TO (position)  O. <400..........  Sequence................  SEQ ID NO should follow the    M.</p><p class="depth2">numeric identifier and</p><p class="depth2">should appear on the line</p><p class="depth2">preceding the actual</p><p class="depth2">sequence. ----------------------------------------------------------------------------------------------------------------   [63 FR 29636, June 1, 1998, as amended at 65 FR 54681, Sept. 8, 2000; 68  FR 38630, June 30, 2003]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
